Literature DB >> 22886251

Intracellular antibody capture (IAC) methods for single domain antibodies.

Tomoyuki Tanaka1, Terence H Rabbitts.   

Abstract

Intracellular single domain antibodies are recombinant proteins, comprising one variable region domain fragment, that bind specifically to intracellular molecules and can interfere with their particular functions within various cellular compartments. They are valuable tools in bioscience and potential macrodrugs in biotherapeutics; however, their application is still limited because of the difficulty and inefficiency of acquisition of functional intracellular antibodies. We describe here the new generation protocol for intracellular antibody capture to facilitate selection of functional single domains. This protocol uses a series of optimized single domain libraries, based on designed intracellular variable (VH or VL) region scaffolds, for direct in vivo isolation of single domains that bind to target proteins and interaction and for affinity maturation to develop sub-nM affinity antibody fragments. The method has advantages over other methods in that specific single domains are isolated directly within the reducing cellular environment and can be selected without in vitro antigen protein preparation.In an accompanying methods paper, we describe a simple extension of the methodology to isolate subsets of IAC-captured single domains that interfere with protein-protein interactions.

Mesh:

Substances:

Year:  2012        PMID: 22886251     DOI: 10.1007/978-1-61779-968-6_10

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  4 in total

Review 1.  Single domain antibodies for the knockdown of cytosolic and nuclear proteins.

Authors:  Thomas Böldicke
Journal:  Protein Sci       Date:  2017-03-24       Impact factor: 6.725

Review 2.  LMO2 at 25 years: a paradigm of chromosomal translocation proteins.

Authors:  Jennifer Chambers; Terence H Rabbitts
Journal:  Open Biol       Date:  2015-06       Impact factor: 6.411

Review 3.  Antibodies inside of a cell can change its outside: Can intrabodies provide a new therapeutic paradigm?

Authors:  Andrea L J Marschall; Stefan Dübel
Journal:  Comput Struct Biotechnol J       Date:  2016-07-31       Impact factor: 7.271

4.  Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds.

Authors:  Abimael Cruz-Migoni; Peter Canning; Camilo E Quevedo; Carole J R Bataille; Nicolas Bery; Ami Miller; Angela J Russell; Simon E V Phillips; Stephen B Carr; Terence H Rabbitts
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-25       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.